NEC Presents Promising Interim Results of AI-Driven Personalized Cancer Vaccine NECVAX-NEO1

NEC's AI-Driven Cancer Vaccine Shows Promise in Phase 1 Trial

NEC Bio Therapeutics, a subsidiary of NEC Corporation, has unveiled promising interim results from its ongoing Phase 1 clinical trial of NECVAX-NEO1, an innovative AI-driven personalized oral cancer vaccine. The findings were presented at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland, marking a significant milestone in the field of personalized cancer immunotherapy 1

1

2

The Technology Behind NECVAX-NEO1

NECVAX-NEO1 represents a cutting-edge approach to cancer treatment, combining artificial intelligence with personalized medicine. The vaccine is a bacteria-based oral DNA therapeutic, designed using AI to predict the most immunogenic patient-specific neoepitopes. This tailored approach aims to activate the patient's immune system, triggering a precise T-cell response against tumor cells based on the individual's unique neoantigens 1

1

2

Phase 1 Trial Results

The Phase 1 basket trial involved five patients with melanoma, renal cell cancer, or head and neck cancer, who had been receiving checkpoint inhibitor (CPI) treatment for at least three months. Key findings from the 24-week interim results include:

1. Safety: The safety run-in phase demonstrated no treatment-related toxicities, allowing for a dose increase 1

   1

   2

   2

   .
2. Immunogenicity: An ELISPOT response was induced by 68% of neoepitopes, with 40% of patients showing significant neoantigen-specific signals 1

   1

   2

   2

   .
3. Disease Control: After the 24-week treatment period, 80% of patients maintained stable disease status, indicating a high disease control rate 1

   1

   2

   2

   .

Related Stories

Evaxion's AI-Designed Cancer Vaccine Shows Promising Results in Phase 2 Trial

Evaxion Biotech Reports Promising Results in Vaccine Development

Evaxion Biotech's AI-Immunology™ Platform Shows Strong Validation in Multiple Clinical Trials

AI-Powered NeoDisc Pipeline Revolutionizes Personalized Cancer Vaccine Design

Expert Commentary

Dr. Heinz Lubenau, CEO of NEC Bio Therapeutics, expressed enthusiasm about the results, stating, "We are very excited about our first proof-of-concept data showing signs of promising immunogenicity and associated biomarker changes in patients." He emphasized the potential of NECVAX-NEO1 as an additional treatment option for patients with difficult-to-treat cancers 1

1

2

Motoo Nishihara, Corporate Executive Vice President and CTO of NEC Corporation, highlighted the significance of NECVAX-NEO1 as NEC's first clinically developed cancer vaccine asset. He noted that this development aligns with NEC's broader mission of providing global healthcare solutions using state-of-the-art technologies 1

1

2

Ongoing Research and Future Prospects

The clinical trial for NECVAX-NEO1 is expanding, with additional sites in Lithuania, Germany, and Spain actively recruiting patients. This expansion aims to generate more comprehensive data on the vaccine's efficacy and safety profile 1

1

2

The poster presentation at the ESMO Immuno-Oncology Congress, titled "Oral DNA vaccination targeting personalised neoantigens in immune checkpoint inhibitor treated solid tumor patients - Interim results," provides detailed insights into the study's methodology and findings 1

1

2

As NEC continues to advance its research in personalized cancer therapies, NECVAX-NEO1 represents a promising step towards more effective and tailored treatment options for cancer patients. The integration of AI in predicting patient-specific neoepitopes showcases the potential of technology in revolutionizing cancer treatment approaches.